These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 26803814)
1. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia. Aljunid S; Orhun NM; Nur AM; Noor MRM; Wan Puteh SE BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814 [TBL] [Abstract][Full Text] [Related]
2. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia. Van Kriekinge G; Sohn WY; Aljunid SM; Soon R; Yong CM; Chen J; Lee IH Asian Pac J Cancer Prev; 2018 Apr; 19(4):933-940. PubMed ID: 29693347 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154 [TBL] [Abstract][Full Text] [Related]
6. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. Li X; Stander MP; Van Kriekinge G; Demarteau N BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918 [TBL] [Abstract][Full Text] [Related]
9. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. Gomez JA; Lepetic A; Demarteau N BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan. Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896 [TBL] [Abstract][Full Text] [Related]
11. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975 [TBL] [Abstract][Full Text] [Related]
12. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082 [TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. Armstrong EP J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Ezat WP; Aljunid S Asian Pac J Cancer Prev; 2010; 11(1):79-90. PubMed ID: 20593935 [TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228 [TBL] [Abstract][Full Text] [Related]
18. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination. Aljunid S; Zafar A; Saperi S; Amrizal M Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014 [TBL] [Abstract][Full Text] [Related]
20. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Burger EA; Campos NG; Sy S; Regan C; Kim JJ Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]